A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Inclusion Criteria

• •Patients must be at least 18 years of age at the time of signing the informed consent.
• •Patients must be willing and able to provide written informed consent
• •Patients must have locally advanced or metastatic solid tumors that have progressed after standard of care therapy or for which no standard therapy exists
• •Tumors must harbor a TP53 R175H variant mutation confirmed by an accredited laboratory-based test
• •Patients must be HLA-A\*02:01 positive by central assay
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at the time of enrollment
• •Adequate hematological, renal and hepatic function
• •Per Investigator judgement, patient is willing and able to complete study visits and/or procedures per the protocol and comply with study requirements for study participation